RedHill Biopharma in Active Talks for Opaganib Collaborations
RDHL sits 42% above its 52-week low of $0.71.
Summary
RedHill Biopharma is actively discussing potential collaborations to advance its investigational oral drug, Opaganib, including for Ebola outbreak biodefense platforms. This news follows a 6-K filed minutes earlier, which specified discussions with the World Health Organization (WHO) and other partners. For a company that recently received a Nasdaq delisting notice and reported a going concern warning, securing partnerships for a key drug candidate is a critical step towards potential funding and continued development.
At the time of this announcement, RDHL was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.